证券代码：002252 证券简称：上海莱士 公告编号：2023-074 公司于 2023 年 6 月 2 日召开了第五届董事会第二十四次（临时）会议，审 议通过了《关于回购公司股份方案的议案》，同意公司使用自有资金以集中竞价 交易方式从二级市场回购公司股份，用于依法注销减少注册资本或实施股权激励 /员工持股计划，其中用于实施股权激励/员工持股计划的股份占本次回购股份总 数的 30%，用于依法注销减少注册资本的股份占本次回购股份总数的 70%。本次 回购股份的资金总额为不低于人民币 5 亿元（含）且不超过人民币 10 亿元（含）， 回购股份的价格不超过人民币 8.00 元/股（含），具体回购股份数量以回购方案实 施完毕时实际回购的股份数量为准。公司于 2023 年 7 月 6 日召开 2023 年第一 1 次临时股东大会审议通过了上述股份回购方案。具体内容详见公司分别于 2023 年 6 月 3 日、2023 年 7 月 7 日在《证券时报》、《中国证券报》、《上海证券报》、 《证券日报》和巨潮资讯网（www.cninfo.com.cn）披露的相关公告。 上海莱士血液制品股份有限公司 关于回购股份注销完成暨股份 ...

证券代码：002252 证券简称：上海莱士 公告编号：2023-073 上海莱士血液制品股份有限公司 关于收购广西冠峰生物制品有限公司95%股权的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 一、交易基本情况 上海莱士血液制品股份有限公司（以下简称"公司"）于 2023 年 11 月 9 日 分别与贺州安信乾能叁期投资基金合伙企业（有限合伙）（"叁期基金"）以及自 然人股东李冠锋先生、韦向红女士、黄科良先生（"自然人股东"）签署了《股权 收购协议》，公司以自有资金人民币 481,278,692 元（含税）收购叁期基金、自然 人股东合计持有的广西冠峰生物制品有限公司（"广西冠峰"）95%股权。广西冠 峰核心资产包括一家位于广西壮族自治区南宁市的具有人血白蛋白、静脉注射用 人免疫球蛋白、人免疫球蛋白三个产品品种、年产能为 200 吨血浆的血液制品生 产企业，以及两个已经建成的单采血浆站（永福冠峰单采血浆有限公司、忻城冠 峰单采血浆有限公司）。该事项详见公司于 2023 年 11 月 11 日刊登在《中国证券 报 》、《 上 海 证 券 报 》、《 证 ...

证券代码：002252 证券简称：上海莱士 上海莱士血液制品股份有限公司 投资者关系活动记录表 编号：2023-012 √ 特定对象调研 □ 分析师会议 投资者关系 □ 媒体采访 □ 业绩说明会 活动类别 □ 新闻发布会 □ 路演活动 □ 现场参观 □ 其他（请文字说明其他活动内容） 参与单位名称 广发基金 王蓄锐 及人员姓名 广发基金 孙琳 时间 2023年 11月15日 13:30—15:00 地点 公司会议室 上市公司 刘 峥 副总经理、董事会秘书 接待人员姓名 褚忠君 市场总监 一、公司介绍 市场总监就血液制品市场情况作简要介绍。 二、交流互动环节 问题 1：公司有哪些竞争优势？ ...

Group 1: Company Overview and Market Position - Shanghai Laishi Blood Products Co., Ltd. operates in a high-demand blood products industry, with overall good sales performance [2][3] - The company focuses on both existing and new plasma source development, emphasizing management improvement and internal growth [3] Group 2: Acquisition and Expansion Plans - The company is in the process of acquiring 95% equity of Guangxi Guanfeng Biological Products Co., Ltd., which is a significant player in the blood products sector [3] - The acquisition aligns with the company's strategic development plan and aims to enhance its presence in Guangxi, a key area for plasma collection [3][4] Group 3: Financial Performance and Projections - GDS, a subsidiary, reported EBITDA figures from 2019 to 2022: $29.48 million (2019), $33.55 million (2020), $30.70 million (2021), and $20.40 million (2022) [4] - The company anticipates stable pricing trends for blood products, influenced by procurement policies and supply-demand dynamics [4] Group 4: Operational Insights - The growth of single plasma collection stations is driven by factors such as regional demographics, local customs, and operational management capabilities [5] - The company has seen significant growth in its import agency business for human albumin and GDS products, although gross margins have been affected by currency fluctuations [5]

证券代码：002252 证券简称：上海莱士 公告编号：2023-072 上海莱士血液制品股份有限公司 关于收购广西冠峰生物制品有限公司股权暨签署《股权收 购协议》的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 特别提示： 1、本次签署的协议为股权受让正式协议，本次交易的资金来源为公司自有 资金，本次交易前目标公司已经评估，交易各方同意以评估结果作为定价依据， 协商确定了标的股权的最终交易价格。本次收购广西冠峰 95%股权的价格总额 为人民币 481,278,692 元（含税）。 2、根据《公司法》、深圳证券交易所《股票上市规则》及《公司章程》等 相关规定，本次股权收购事项在公司总经理审批权限范围内，无需提交公司董事 会及股东大会审议。 3、本次股权收购事项不构成关联交易，亦不构成《上市公司重大资产重组 管理办法》规定的重大资产重组。 一、交易概述 上海莱士血液制品股份有限公司（"公司"、"上海莱士"）已于 2023 年 11 月 9 日分别与贺州安信乾能叁期投资基金合伙企业（有限合伙）（"叁期基 金"）以及自然人股东李冠锋先生、韦向红女士、黄科良先生（ ...

证券代码：002252 证券简称：上海莱士 上海莱士血液制品股份有限公司 投资者关系活动记录表 编号：2023-010 √特定对象调研 □分析师会议 投资者关系 □媒体采访 □业绩说明会 活动类别 □新闻发布会 □路演活动 □现场参观 □其他（请文字说明其他活动内容） 参与单位名称 Cobas Asset Management 詹明昆 及人员姓名 时间 2023年 11月3日 14:00—15:30 地点 公司会议室 上市公司 刘 峥 副总经理、董事会秘书 接待人员姓名 陈乐奇 财务负责人 褚忠君 市场总监 一、公司介绍 1、财务负责人就公司财务情况作简要介绍； 2、市场总监就血液制品市场情况作简要介绍。 ...

Group 1: Company Overview - Shanghai Laishi Blood Products Co., Ltd. is one of the largest blood product manufacturers in China, focusing on human serum albumin, intravenous immunoglobulin, specific immunoglobulin, and coagulation factor products [2][3]. - The company has established a partnership with GDS for the exclusive distribution of certain products in mainland China [3]. Group 2: Product Structure and Market Trends - The product structure is primarily composed of human serum albumin and intravenous immunoglobulin, which are currently in a state of supply-demand balance [2]. - There is significant growth potential in the market demand for coagulation factor products, prompting the company to enhance the utilization rate of raw plasma [2]. Group 3: Sales Performance - The blood products industry is experiencing high demand, and the company's overall sales performance is strong, supported by a professional marketing team and brand effect [3][4]. - The company employs a multi-channel sales strategy, with both hospital and outpatient sales for its albumin products, while other blood products primarily focus on hospital sales [4]. Group 4: Pricing Trends - Blood product prices are currently stable, influenced mainly by supply and demand dynamics [3]. Group 5: Future Growth and Development - The growth in single plasma collection stations is driven by factors such as regional outreach, local population, cultural practices, and operational management capabilities [3]. - The demand for immunoglobulin products is expected to increase due to healthcare reforms, rising disposable income, and improved awareness among clinical practitioners [3].

Financial Performance - The company's revenue for Q3 2023 reached ¥2,034,744,817.97, representing a 22.72% increase compared to the same period last year[3]. - Net profit attributable to shareholders for Q3 2023 was ¥548,605,548.04, a slight increase of 1.08% year-on-year[3]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥603,604,791.17, up 11.36% from the previous year[3]. - Total operating revenue for the current period reached ¥5,935,370,613.02, a 19.9% increase from ¥4,951,543,979.15 in the previous period[25]. - Net profit for the current period was ¥1,785,618,617.73, representing a 11.6% increase compared to ¥1,599,553,187.66 in the previous period[26]. - Total comprehensive income for the current period was ¥2,242,597,415.86, down from ¥3,068,200,086.26 in the previous period[26]. Assets and Liabilities - The total assets at the end of Q3 2023 amounted to ¥31,912,459,945.21, reflecting a 4.78% increase from the end of the previous year[3]. - As of September 30, 2023, total assets amounted to approximately 31.91 billion yuan, an increase from 30.46 billion yuan at the beginning of the year[22]. - The total liabilities as of September 30, 2023, were approximately 2.09 billion yuan, compared to 1.64 billion yuan at the beginning of the year[23]. - The company's total equity increased to approximately 29.82 billion yuan as of September 30, 2023, from 28.81 billion yuan at the beginning of the year[23]. Cash Flow - The company's cash flow from operating activities for the year-to-date reached ¥1,940,451,824.32, a significant increase of 61.25% compared to the same period last year[7]. - Operating cash flow net amount was ¥1,940,451,824.32, an increase of 61.4% from ¥1,203,356,366.64 in the previous period[29]. - Cash and cash equivalents at the end of the period totaled ¥3,580,923,338.88, up from ¥2,243,907,832.11 at the end of the previous period[29]. - The company's cash and cash equivalents stood at approximately 4.02 billion yuan as of September 30, 2023, up from 3.98 billion yuan at the beginning of the year[21]. Shareholder Information - As of September 28, 2023, the total number of common shareholders is 103,398[9]. - GRIFOLS, S.A. holds 26.20% of shares, totaling 1,766,165,808 shares, making it the largest shareholder[9]. - The top ten shareholders include several state-owned and foreign entities, with significant stakes held by China Cinda Asset Management Co., Ltd. (4.14%) and China Huarong Asset Management Co., Ltd. (3.65%)[9]. - The company confirmed that there are no related party transactions among the top ten shareholders, except for certain relationships within the CITIC Group[10]. Share Repurchase Plan - The company has implemented a share buyback plan, resulting in a net cash outflow of ¥1,088,886,701.78 from financing activities[7]. - The company has repurchased a total of 136,153,070 shares, representing 2.0198% of the total share capital, with a total expenditure of approximately RMB 999.69 million[15]. - The highest repurchase price was RMB 7.56 per share, while the lowest was RMB 7.06 per share[15]. - The repurchase plan was approved with a total budget of between RMB 500 million and RMB 1 billion, with a maximum price of RMB 8.00 per share[12]. - The first repurchase occurred on July 14, 2023, with 6,531,878 shares bought back at a total cost of approximately RMB 48.78 million[13]. - The company has disclosed the progress of the share repurchase on multiple occasions, including on August 3, 5, and 21, 2023[14]. - The repurchase plan is set to be completed within 12 months from the approval date, contingent on specific conditions being met[12]. Employee Stock Ownership Plan (ESOP) - The employee stock ownership plan (ESOP) aims to use up to 33.77 million repurchased shares, accounting for approximately 0.50% of the total share capital of 674.08 million shares[16]. - The total amount of funds raised through the ESOP is expected to be no more than 121.91 million yuan, with actual subscription funds amounting to 113.17 million yuan as of September 25, 2023[16]. - The company has completed the non-trading transfer of 31.35 million shares to the ESOP account at a transfer price of 3.61 yuan per share, representing 0.47% of the total share capital[17]. Operational Metrics - The gross profit margin decreased due to an increase in the sales proportion of imported albumin, which has a lower gross margin compared to self-produced products[7]. - The company reported a 19.87% increase in total revenue for the year-to-date, driven primarily by growth in imported albumin and immunoglobulin sales[6]. - The company experienced a 38.42% increase in accounts payable, mainly due to increased payables from agency import business[6]. - The company reported a decrease in contract liabilities by 88.63%, indicating a reduction in advance payments received[6]. - The company reported a decrease in accounts receivable from approximately 707.02 million yuan to 654.86 million yuan during the same period[21]. - The company’s inventory increased from approximately 3.27 billion yuan to 3.37 billion yuan as of September 30, 2023[21]. - Research and development expenses for the current period were ¥132,454,755.35, a 29.7% increase from ¥102,089,434.95 in the previous period[25].

证券代码：002252 证券简称：上海莱士 公告编号：2023-070 上海莱士血液制品股份有限公司 关于第五届董事会第二十八次（临时）会议决议公告 上海莱士血液制品股份有限公司（"公司"）第五届董事会第二十八次（临时） 会议于 2023 年 10 月 18 日以电话和邮件方式发出会议通知，并于 2023 年 10 月 23 日下午 3 点以通讯方式召开。 本次会议应出席董事 9 名，实际出席会议董事 9 名。本次会议由公司董事长、 总经理 Jun Xu（徐俊）先生主持。会议的召集、召开与表决程序符合《公司法》 和《公司章程》等有关规定。会议在保证所有董事充分发表意见的前提下，全体 与会董事经投票表决，一致作出如下决议： 1、审议通过《2023 年第三季度报告》 表决结果：9票同意、0票反对、0票弃权。 《2023年第三季度报告》刊登于《证券时报》、《中国证券报》、《上海证券报》、 《证券日报》和巨潮资讯网（www.cninfo.com.cn），供投资者查阅。 特此公告。 上海莱士血液制品股份有限公司 董事会 二〇二三年十月二十五日 1 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载 ...

证券代码：002252 证券简称：上海莱士 公告编号：2023-069 上海莱士血液制品股份有限公司 第一期员工持股计划第一次持有人会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 二、持有人会议审议情况 与会持有人逐项审议并通过了如下议案： （一）审议并通过《关于设立公司第一期员工持股计划管理委员会的议案》 为保证本次员工持股计划的顺利实施，保障持有人的合法权益，根据公司《第 一期员工持股计划》和公司《第一期员工持股计划管理办法》的相关规定，公司 拟设立本员工持股计划管理委员会，作为本员工持股计划的日常管理与监督机构， 代表持有人行使员工持股计划资产所对应的股东权利。员工持股计划管理委员会 由 3 名委员组成，设管理委员会主任 1 人，管理委员会委员的任期与本员工持股 计划的存续期一致。 表决结果：同意 113,173,500 份，占出席会议的持有人所持有表决权份额总 1本员工持股计划本次实际认购人数 268 人（不含预留份额），对应实际认购股份 3,135 万股，本次认购价 格为 3.61 元/股。本员工持股计划以"份"作为认购单位，每份份额为 ...